Navigation Links
OHSU Cancer Institute researchers find connection between protein, prognosis in breast cancer

PORTLAND, Ore. Oregon Health & Science University Cancer Institute researchers have found that a tumor protein present in an aggressive form of breast cancer is related to a poor prognosis.

The presence of the protein, called growth factor receptor-bound protein-7, often referred to as GRB-7, in breast cancer tumors, is strongly related to the growth and spread of the cancer, according to principal investigator Shiuh-Wen Luoh, M.D., Ph.D., assistant professor of medicine (hematology/medical oncology) in the OHSU School of Medicine.

The research will be presented Sunday, April 13, at 1 p.m. at the annual American Association for Cancer Research meeting in San Diego.

The GRB-7 protein previously has been shown to be important to cell communication in the spread of cancer. The GRB-7 gene is located close to the HER-2/Neu gene that regulates breast cancer growth. The OHSU Cancer Institute researchers discovered that the levels of GRB-7 protein are often heightened at the same time that HER-2/Neu levels are high. Also, not infrequently, they found breast tumors that overexpressed one but not the other protein. Overexpression means that there is an abundant presence of the protein.

It is surprising that we found discordance in the overexpression of these genes because they are so close together, Luoh said.

Researchers analyzed 563 primary breast cancer specimens. The samples were collected during a 20 year period for the OHSU Cancer Institute Breast Tumor and Clinical Data Repository.

The OHSU study shows that one in six breast tumors have high GRB-7 protein. These tumors have more aggressive, fast-growing and fast-spreading characteristics. HER-2/Neu positive tumors do not show these same features.

We think that identifying the individual contribution of the GRB-7 and its interaction with HER-2/ Neu gene may eventually help physicians better predict the clinical course of breast cancer in their patients. Also, new treatments might be designed to interfere with the actions of GRB-7 that can stop the growth and spread of a portion of breast cancer tumors, Luoh said.

Researchers have known that not all HER-2/Neu positive breast cancers shrink or slow their growth when treated with Trastuzumab or Lapatinib, targeted therapies against HER-2/Neu. The researchers speculate that GRB-7 might influence a tumors response to treatment. These findings are preliminary but could eventually lead to a clinical test for GRB-7 and better treatment for patients with GRB-7 positive breast tumors, Luoh explained.


Contact: Christine Decker
Oregon Health & Science University

Related medicine news :

1. Drinking May Raise Breast Cancer Risk
2. Biomarker May Predict Response to Cancer Therapy
3. Breast Cancer Vaccine Works Against Deadlier Form of Disease
4. Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component
5. Penn researchers find targeted therapy combination overcomes treatment resistance in liver cancer
6. Susan G. Komen for the Cure(R) Calls on Policymakers to Address Unfairness in Breast Cancer Incidence and Mortality
7. Radiation beneficial for older breast cancer patients
8. Cancer Drug Trials Often Halted Early
9. Mammography plus sonography can help rule out breast cancer in patients with palpable lesions
10. Newly diagnosed breast cancer patients benefit from use of USFNA of lymph nodes
11. New technique in treating patients with liver cancer proves effective
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... For the first time, Vitalalert ... Organizations, One Beat ” campaign. The partnership between the two groups began in 2014 ... MAP International’s cause. , MAP International was founded in 1954 and is an international ...
(Date:11/25/2015)... ... ... On November 25, 2015, officials of Narconon Arrowhead , the drug rehabilitation ... new cutting edge recovery program that has been 50 years in the making. ... with the purpose to free addicts from the symptoms and negative behaviors of addiction. ...
(Date:11/25/2015)... ... ... Smiles by Stevens is pleased to announce the addition of Botox® for ... aware of the benefits of Botox® in the treatment of moderate facial wrinkling, few ... and pain as a result of Jaw Tension, TMJ (temporo-mandibular joint) disorder, and Bruxism ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical Study conducted by an ... IL, UV Angel is evaluating the efficacy of its product and its disinfection protocol. ... 30 beds) from May 2014 through October 2015 at a 360-bed, acute-care, academic medical ...
(Date:11/25/2015)... Spring, Md (PRWEB) , ... November 25, 2015 ... ... Pulmonary Hypertension Association (PHA) announces the nation’s Periwinkle Pioneers, individuals and groups responsible ... history of this disease. The Periwinkle Pioneers, nominated by the public, will receive ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... 2015 Kitov Pharma ceuticals ... a biopharmaceutical company focused on the development of therapeutic ... today announced the closing of its previously announced underwritten ... ), each representing 20 ordinary shares of the Company, ... ADSs and warrants were issued in a fixed combination ...
(Date:11/25/2015)...  Today AVACEN Medical announced the issue of United States patent No. ... ". This patent shields the company,s AVACEN 100 dry heat therapy medical device and specific methods ... Photo - ... ... ...
(Date:11/25/2015)... , Nov. 25, 2015 USP 800 ... drug preparations (e.g. pharmacists, pharmacy technicians, nurses, physicians, ... technicians). The chapter also covers all entities which ... pharmacies, hospitals, other healthcare institutions, patient treatment clinics, ... --> --> What is ...
Breaking Medicine Technology: